Immupharma (IMM) RNS Announcements

Add to Alert list
Date Time Source Announcement
22 Nov 2022 03:15 PM
RNS
Holding(s) in Company
14 Nov 2022 04:40 PM
RNS
Second Price Monitoring Extn
14 Nov 2022 04:35 PM
RNS
Price Monitoring Extension
11 Nov 2022 07:31 AM
RNS
Lupuzor Update
11 Oct 2022 04:40 PM
RNS
Second Price Monitoring Extn
11 Oct 2022 04:35 PM
RNS
Price Monitoring Extension
07 Oct 2022 04:44 PM
RNS
Company Secretary Change
30 Sep 2022 07:30 AM
RNS
Lupuzor Update
30 Sep 2022 07:00 AM
RNS
Interim Results or the 6mths Ended 30 June 2022
29 Sep 2022 04:40 PM
RNS
Second Price Monitoring Extn
29 Sep 2022 04:37 PM
RNS
Price Monitoring Extension
14 Sep 2022 10:04 AM
RNS
Written Response received from the FDA
07 Sep 2022 08:25 AM
RNS
Exercise of Options
31 Aug 2022 07:00 AM
RNS
FDA response for Type C Meeting - update
30 Aug 2022 11:29 AM
RNS
Exercise of Options
24 Aug 2022 08:11 AM
RNS
Exercise of Options
17 Aug 2022 06:12 PM
RNS
TR-1 Notification of major holdings
16 Aug 2022 08:03 AM
RNS
Total Voting Rights
11 Aug 2022 07:00 AM
RNS
Result of Broker Option / PDMR Dealings
04 Aug 2022 07:00 AM
RNS
Investor Presentation - Investor Meet Company
03 Aug 2022 04:40 PM
RNS
Second Price Monitoring Extn
03 Aug 2022 04:35 PM
RNS
Price Monitoring Extension
03 Aug 2022 04:33 PM
RNS
Subscription/Placing to raise £1.1m; Broker Option
26 Jul 2022 04:41 PM
RNS
Second Price Monitoring Extn
26 Jul 2022 04:35 PM
RNS
Price Monitoring Extension
11 Jul 2022 07:00 AM
RNS
Initiation of Research
07 Jul 2022 07:00 AM
RNS
Confirmed FDA response date for Type C Meeting
28 Jun 2022 05:44 PM
RNS
Admission of new ordinary shares of £0.01
28 Jun 2022 11:42 AM
RNS
Result of AGM
27 Jun 2022 07:00 AM
RNS
Update on Lupuzor
20 Jun 2022 03:22 PM
RNS
Holding(s) in Company
01 Jun 2022 07:00 AM
RNS
Notice of AGM & Annual Report & Accounts
25 May 2022 07:00 AM
RNS
Finals results for y/e 31 December 2021
04 May 2022 07:00 AM
RNS
UPDATE on LUPUZORT PROGRESS to PHASE 3 with AVION
13 Apr 2022 07:00 AM
RNS
UPDATE on P140 (LUPUZORT) clinical progress
07 Feb 2022 07:00 AM
RNS
LUPUZOR UPDATE
10 Jan 2022 07:00 AM
RNS
TR-1: Notification of major holdings
05 Jan 2022 09:53 AM
RNS
TR-1: Notification of major holdings
24 Dec 2021 08:34 AM
RNS
Holding(s) in Company
20 Dec 2021 07:00 AM
RNS
Subscriptions and Placing to raise £3.55 million
15 Dec 2021 04:35 PM
RNS
Price Monitoring Extension
07 Dec 2021 04:41 PM
RNS
Second Price Monitoring Extn
07 Dec 2021 04:36 PM
RNS
Price Monitoring Extension
29 Nov 2021 07:00 AM
RNS
COLLABORATION WITH IMPERIAL COLLEGE LONDON
18 Nov 2021 07:00 AM
RNS
Corporate Update
08 Nov 2021 04:41 PM
RNS
Second Price Monitoring Extn
08 Nov 2021 04:36 PM
RNS
Price Monitoring Extension
11 Oct 2021 04:35 PM
RNS
Price Monitoring Extension
01 Oct 2021 07:00 AM
RNS
Euronext Delisting
30 Sep 2021 07:15 AM
RNS
PROF. SYLVIANE MULLER AWARDED 'LEGION D'HONNEUR'

ImmuPharma is a pharma company headquartered in London with its research R&D team, ImmuPharma Biotech, based in France. 

ImmuPharma listed on AIM under the ticker IMM. 

IMM research strategy is based on two strategic axes: research based on external collaboration aimed at discovering new active ingredients, which has led to the development of our most advanced project in terms of clinical development: P140 an active peptide against the auto-immune disease, Lupus SLE and internal research based on the use of molecular programming technologies, which has notably led to the development of the BioAMB and BioCIN projects.

IMM share price listed in London at 1,190p in 2000. 

UK 100